Today's journal articles

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation.

Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Adenovirus Targeting to Prostate-specific Membrane Antigen through Virus-displayed Semi-random Peptide Library Screening.

Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.

IL-15R{alpha}-IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation.

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck.

Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.

A combination of DR5 agonistic mAb with gemcitabine targets pancreatic cancer stem cells, and results in long-term disease control in human pancreatic cancer model.

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.

The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages.

Cost-effectiveness of human papillomavirus vaccination and screening in Spain.

A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma.

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematological malignancie.

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.

Today's News Items

AGENSYS, AN AFFILIATE OF ASTELLAS, ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF AGS-16M8F FOR RENAL CANCER

Daiichi Sankyo Files for Approval to Manufacture and Market AMG 162 (Denosumab) in Japan

Training Courses & Meetings

No events listed

Previous News Items

No previous news items today

---

For faster discovery, automatically organize PubMed results into categories